GO:0045737 positive regulation of cyclin-dependent protein serine/threonine kinase activity: Cell Cycle Control Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045737 describes any process that activates or increases the frequency, rate or extent of cyclin-dependent protein serine/threonine kinase (CDK) activity.
• CDK activation is driven by binding to cyclin partners, activating phosphorylation by CDK-activating kinase (CAK), and removal of inhibitory phosphorylations.
• MYC and E2F transcription factors amplify CDK gene expression and reinforce positive feedback loops that sustain cell cycle progression.
• Dysregulated positive regulation of CDK activity is a hallmark of cancer and a validated target for CDK4/6 inhibitors such as palbociclib.
• CDK activity also contributes to senescence, neuronal function, and stress responses, extending its relevance beyond proliferation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of CDK regulatory networks.
Description
GO:0045737, positive regulation of cyclin-dependent protein serine/threonine kinase activity, is a biological process term that captures any mechanism that activates or increases the frequency, rate or extent of CDK activity. CDKs are serine/threonine kinases that require association with regulatory cyclin subunits and specific phosphorylation events to become catalytically competent, and their activity is tightly controlled during the cell cycle. This GO term is therefore central to understanding how cells commit to division, respond to growth signals, and coordinate transcription with DNA replication and mitosis. Researchers study GO:0045737 because its dysregulation is directly linked to cancer, where oncogenic drivers such as MYC and E2F sustain high CDK activity, and because pharmacological inhibition of CDKs has become a standard therapeutic strategy in breast cancer and other malignancies. Beyond proliferation, positive regulation of CDK activity influences senescence, neuronal development, and plant stress signaling, making it a broadly relevant process across model systems.
positive regulation of cyclin-dependent protein serine/threonine kinase activity At A Glance
| GO ID | GO:0045737 |
|---|---|
| GO term | positive regulation of cyclin-dependent protein serine/threonine kinase activity |
| Ontology | biological_process |
| Definition | Any process that activates or increases the frequency, rate or extent of CDK activity. |
| Synonyms | activation of cyclin-dependent protein kinase activity; positive regulation of CDK activity; positive regulation of cyclin-dependent protein kinase activity; stimulation of cyclin-dependent protein kinase activity; up regulation of cyclin-dependent protein kinase activity; up-regulation of cyclin-dependent protein kinase activity; upregulation of cyclin-dependent protein kinase activity |
| Major function | Drives cell cycle progression by activating CDK-cyclin complexes. |
| Key regulators | Cyclins, CAK, CDC25 phosphatases, MYC, E2F. |
| Disease relevance | Cancer, senescence, neuronal disorders, stress responses. |
| Research methods | CRISPR KO/KI, phosphoproteomics, kinase assays, RNA-seq. |
What Is GO:0045737?
In practical terms, GO:0045737 encompasses all molecular events that turn CDK enzymes on or keep them active. This includes the binding of cyclin partners that relieve autoinhibition, activating phosphorylation of the CDK T-loop by CAK, dephosphorylation of inhibitory residues by CDC25 phosphatases, and transcriptional or post-translational changes that increase the amount or specific activity of CDK-cyclin complexes. The term is defined by its outcome: an increase in CDK serine/threonine kinase activity, regardless of the upstream mechanism.
Why Is positive regulation of cyclin-dependent protein serine/threonine kinase activity Important in Cell Biology?
Positive regulation of CDK activity is a decisive control point for cell division, and its perturbation is causally linked to cancer, where oncogenes such as MYC and E2F elevate CDK expression and activity. Pharmacological inhibitors of CDK4/6, including palbociclib, have validated this process as a therapeutic target in estrogen receptor-positive breast cancer. Moreover, CDK activity influences senescence through lamin B1 loss, neuronal function via CDK5-mediated Sox6 regulation, and plant salt tolerance through CDK8 module activity, demonstrating its broad biological significance.
• Controls G1/S and G2/M transitions by activating CDK-cyclin complexes.
• Integrates growth factor and oncogenic signaling through MYC and E2F.
• Is a validated drug target in breast cancer and multiple myeloma.
• Contributes to senescence-associated phenotypes such as lamin B1 loss.
• Regulates neuronal gene expression via CDK5 and Sox6.
• Modulates stress responses in plants through CDK8-AHL10-SUVH2/9.
• Underlies resistance mechanisms to CDK4/6 inhibitors.
• Provides a mechanistic basis for CRISPR screens targeting cell cycle regulators.
What Happens During positive regulation of cyclin-dependent protein serine/threonine kinase activity?
Cyclin binding and CDK activation
In simple terms: Cyclins are the on-switches that bind CDKs and change their shape so they can work.
The primary step in positive regulation of CDK activity is the association of a CDK with its regulatory cyclin subunit. Cyclin binding induces conformational changes that align the catalytic cleft and relieve autoinhibition, enabling substrate phosphorylation. MYC-driven cell cycle progression depends on timely expression of cyclins that partner with CDK4/6, CDK2, and CDK1, thereby increasing overall CDK activity.
Activating phosphorylation by CAK
In simple terms: A second kinase adds a phosphate to the CDK to fully turn it on.
Full activation of CDKs requires phosphorylation of a conserved threonine residue in the T-loop by the CDK-activating kinase (CAK) complex, which contains CDK7. In multiple myeloma, CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities, highlighting how CAK activity feeds into positive regulation of CDK activity.
Removal of inhibitory phosphorylations
In simple terms: Phosphatases erase inhibitory marks to keep CDKs active.
CDC25 phosphatases remove inhibitory phosphates from CDK Thr14 and Tyr15, a required step for full CDK activation at cell cycle checkpoints. This dephosphorylation event is a canonical mechanism of positive regulation of CDK activity and is often deregulated in cancer.
Transcriptional amplification by MYC and E2F
In simple terms: Oncogenic transcription factors make more CDK and cyclin proteins.
MYC and E2F transcription factors promote the expression of multiple CDK and cyclin genes, creating positive feedback loops that sustain high CDK activity. This transcriptional amplification is a key node in GO:0045737 and a driver of proliferative and metabolic vulnerabilities in cancer cells.
Integration with stress and developmental signals
In simple terms: CDK activation is not only for division; it also responds to stress and development.
In Arabidopsis, salt stress activates the CDK8-AHL10-SUVH2/9 module to dynamically regulate salt tolerance, showing that positive regulation of CDK activity operates in environmental stress contexts. In the brain, CDK5 regulates Sox6, linking CDK activity to neuronal gene expression.
Key Genes Involved in GO:0045737 positive regulation of cyclin-dependent protein serine/threonine kinase activity
The following genes and proteins are central to positive regulation of cyclin-dependent protein serine/threonine kinase activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYC | Transcriptionally amplifies CDK and cyclin expression | Oncogenic driver of CDK activity |
| E2F | Promotes CDK and cyclin gene transcription | Feedback loop in proliferation |
| CDK7 | Catalytic subunit of CAK that phosphorylates CDKs | Therapeutic target in multiple myeloma |
| CDK4 | G1 phase kinase activated by D-type cyclins | Target of palbociclib |
| CDK6 | G1 phase kinase activated by D-type cyclins | Target of CDK4/6 inhibitors |
| CDK2 | S phase kinase activated by E-type cyclins | Cell cycle progression |
| CDK1 | Mitotic kinase activated by cyclin B | G2/M transition |
| CDK5 | Neuronal kinase activated by p35/p39 | Regulates Sox6 in brain |
| CDK8 | Mediator kinase module component | Salt stress signaling in plants |
| CCND1 | Cyclin D1, activates CDK4/6 | Breast cancer and CDK4/6 inhibitor response |
| CCNE1 | Cyclin E1, activates CDK2 | S phase entry |
| CCNB1 | Cyclin B1, activates CDK1 | Mitosis |
| CDC25A | Phosphatase removing inhibitory phosphates | CDK activation |
| CDC25C | Phosphatase removing inhibitory phosphates | Mitotic CDK activation |
| AR | Tumor suppressor in ER+ breast cancer | Modulates CDK4/6 inhibitor response |
| LMNB1 | Lamin B1, senescence biomarker | CDK activity and senescence |
| SOX6 | Transcription factor regulated by CDK5 | Neuronal function |
How Is positive regulation of cyclin-dependent protein serine/threonine kinase activity Regulated?
Positive regulation of CDK activity is controlled at multiple levels. Transcriptionally, MYC and E2F increase the expression of CDKs and cyclins, creating feed-forward loops. Post-translationally, CAK-mediated phosphorylation and CDC25-mediated dephosphorylation activate CDKs, while inhibitory phosphorylation and CKIs restrain them. In cancer, resistance to CDK4/6 inhibitors can arise through bypass mechanisms that sustain CDK activity, including changes in cyclin D1, CDK6, and upstream signaling. Additionally, the androgen receptor can act as a tumor suppressor in ER+ breast cancer, influencing CDK4/6 inhibitor sensitivity.
positive regulation of cyclin-dependent protein serine/threonine kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYC | Multiple cancers, proliferation | MYC overexpression and knockout cell lines |
| CDK4 | Breast cancer, CDK4/6 inhibitor response | CDK4 knockout and point-mutation models |
| CDK6 | Breast cancer, resistance to CDK4/6 inhibitors | CDK6 overexpression and knockout |
| CDK7 | Multiple myeloma | CDK7 knockout and inhibitor studies |
| LMNB1 | Senescence | LMNB1 knockout and senescence markers |
Cancer and CDK4/6 inhibitor resistance
Dysregulated positive regulation of CDK activity is a hallmark of cancer. MYC and E2F drive high CDK activity, and CDK4/6 inhibitors such as palbociclib are approved for breast cancer. Resistance mechanisms include alterations in cyclin D1, CDK6, and upstream signaling pathways. The androgen receptor can modulate CDK4/6 inhibitor response in ER+ breast cancer, acting as a tumor suppressor in this context.
Senescence
Lamin B1 loss is a senescence-associated biomarker, and changes in CDK activity contribute to the senescence program. Positive regulation of CDK activity can delay or bypass senescence, linking this GO term to aging and tumor suppression.
Neuronal function
CDK5 regulates Sox6 in the brain, demonstrating that positive regulation of CDK activity is important for neuronal gene expression and development. Dysregulation of CDK5 has been implicated in neurodegenerative contexts, although specific disease mechanisms require further study.
Plant stress responses
In Arabidopsis, salt stress activates the CDK8-AHL10-SUVH2/9 module to dynamically regulate salt tolerance, showing that positive regulation of CDK activity extends to environmental stress adaptation.
From positive regulation of cyclin-dependent protein serine/threonine kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CDK4 block proliferation? | CDK4 knockout cell line |
| Does a specific CDK mutation alter inhibitor sensitivity? | CDK4/6 point-mutation knock-in |
| Does tagging CDK7 affect CAK complex assembly? | CDK7 tagged knock-in |
| Does MYC overexpression increase CDK activity? | MYC overexpression cell line |
| Does CDK5 regulate Sox6 in neurons? | CDK5 knockout or overexpression in neuronal cells |
| Does CDK8 module regulate salt tolerance? | CDK8 knockout in Arabidopsis |
How to Study the positive regulation of cyclin-dependent protein serine/threonine kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Kinase assay | CDK enzymatic activity | Validate activators or inhibitors |
| Phosphoproteomics | CDK substrate phosphorylation | Map signaling changes |
| RNA-seq | Gene expression of CDKs and cyclins | Transcriptional regulation |
| CRISPR screen | Genes affecting CDK activity | Identify regulators |
| Western blot | Protein levels and phosphorylation | Confirm activation states |
| Flow cytometry | Cell cycle distribution | Assess proliferation |
| Senescence assay | Lamin B1 loss, beta-galactosidase | Measure senescence |
Kinase activity assays
In vitro kinase assays using recombinant CDK-cyclin complexes and specific substrates measure the direct activity of CDKs and can be used to validate positive regulation.
Phosphoproteomics
Mass spectrometry-based phosphoproteomics identifies CDK substrate phosphorylation events and quantifies changes in CDK activity across conditions.
Transcriptomics
RNA-seq measures expression of CDKs, cyclins, and regulators such as MYC and E2F, providing insight into transcriptional mechanisms of positive regulation.
CRISPR screens
Genome-wide CRISPR knockout or activation screens can identify genes that positively regulate CDK activity and are required for proliferation.
How CRISPR Can Be Used to Study GO:0045737 positive regulation of cyclin-dependent protein serine/threonine kinase activity
Knockout
CRISPR knockout of CDKs, cyclins, or upstream regulators such as MYC and E2F can abolish positive regulation of CDK activity and reveal essential genes for proliferation.
Point Mutation
Point mutations in CDK catalytic residues or regulatory phosphorylation sites can dissect the contribution of specific phosphorylation events to CDK activation and inhibitor sensitivity.
Knock-in
Knock-in of tagged CDKs or cyclins allows affinity purification and live-cell imaging of CDK complexes, enabling precise tracking of positive regulation.
Overexpression
Overexpression of MYC, E2F, or cyclins can drive supraphysiological CDK activity, modeling oncogenic states and CDK4/6 inhibitor resistance.
How EDITGENE Supports positive regulation of cyclin-dependent protein serine/threonine kinase activity Research
Researchers studying positive regulation of cyclin-dependent protein serine/threonine kinase activity-related genes often need to determine whether a candidate gene is causally involved in CDK activation, cell cycle progression, or drug response. EDITGENE provides CRISPR-based cell models and screening services to enable these investigations.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of cyclin-dependent protein serine/threonine kinase activity research.
Frequently Asked Questions About positive regulation of cyclin-dependent protein serine/threonine kinase activity
What is GO:0045737?
GO:0045737 is the Gene Ontology term for positive regulation of cyclin-dependent protein serine/threonine kinase activity, describing any process that activates or increases CDK activity.
What genes are involved in positive regulation of CDK activity?
Key genes include MYC, E2F, CDK7, CDK4, CDK6, CDK2, CDK1, CDK5, CDK8, CCND1, CCNE1, CCNB1, CDC25A, and CDC25C.
How is CDK activity activated?
CDK activity is activated by cyclin binding, CAK-mediated phosphorylation, and removal of inhibitory phosphorylations by CDC25 phosphatases.
Why is positive regulation of CDK activity important in cancer?
Oncogenic drivers such as MYC and E2F sustain high CDK activity, and CDK4/6 inhibitors like palbociclib are used in breast cancer.
What diseases are linked to CDK activity?
Cancer, senescence, neuronal disorders, and plant stress responses are linked to CDK activity.
How can I study positive regulation of CDK activity?
Methods include kinase assays, phosphoproteomics, RNA-seq, and CRISPR screens.
What is the role of CDK7 in CDK activation?
CDK7 is the catalytic subunit of CAK, which phosphorylates CDKs to activate them.
What is the role of MYC in CDK activity?
MYC transcriptionally amplifies CDK and cyclin expression, increasing CDK activity.
How does CDK5 regulate Sox6?
CDK5 phosphorylates and regulates Sox6 in the brain, influencing neuronal gene expression.
What CRISPR models are available for CDK research?
EDITGENE offers knockout, point mutation, knock-in, overexpression, and library screening models for CDK-related genes.
Conclusion
GO:0045737, positive regulation of cyclin-dependent protein serine/threonine kinase activity, is a central biological process that governs cell cycle progression and is frequently dysregulated in cancer and other diseases. Understanding its mechanisms through CRISPR-based models and multi-omics approaches can reveal new therapeutic targets and resistance mechanisms. EDITGENE provides comprehensive services to accelerate this research.
References
- 1. Bretones G et al.. 2015. Myc and cell cycle control.. Biochim Biophys Acta 1849(5):506-16 PMID: 24704206
- 2. Guo P et al.. 2025. Salt stress activates the CDK8-AHL10-SUVH2/9 module to dynamically regulate salt tolerance in Arabidopsis.. Nat Commun 16(1):2454 PMID: 40074748
- 3. Freund A et al.. 2012. Lamin B1 loss is a senescence-associated biomarker.. Mol Biol Cell 23(11):2066-75 PMID: 22496421
- 4. Yao Y et al.. 2023. CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.. Blood 141(23):2841-2852 PMID: 36877894
- 5. Hickey TE et al.. 2021. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer.. Nat Med 27(2):310-320 PMID: 33462444
- 6. Gomatou G et al.. 2021. Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.. Mol Biol Rep 48(1):915-925 PMID: 33409716
- 7. Rudrabhatla P et al.. 2014. Regulation of Sox6 by cyclin dependent kinase 5 in brain.. PLoS One 9(3):e89310 PMID: 24662752
- 8. Dhillon S. 2015. Palbociclib: first global approval.. Drugs 75(5):543-51 PMID: 25792301
